Supporting Information

Novel 2-(5-Aryl-4,5-dihydropyrazol-1-yl)thiazol-4-one as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights

Tarfah Al-Warhi, Ahmed M. El Kerdawy, Mohamed A. Said, Amgad Albohy, Zainab M. Elsayed, Nada Aljaeed, Eslam B. Elkaeed, Wagdy M. Eldehna^{*}, Hatem A. Abdel-Aziz, Miral A. Abdelmoaz

Tables of Contents

1.	Anti-proliferative Activity Against Breast Cancer Cell Lines	2
2.	Cell Cycle Analysis	2
3.	AnnexinV-FITC/PI Apoptosis Assay	3
4.	EGFR Kinase Inhibitory Activity	3
5.	Molecular Docking Study	4-5
6.	Characterisation of the key intermediate (5c) and the target compounds (7a-o)	6
7.	Cells distribution of Cell cycle	6-12
8.	NMR Spectra	13-37
9.	Elemental analysis data	38

1. Anti-proliferative action toward cancer cell lines

The two examined lung cancer cell line A549 and the breast cancer cell line T-47D have been obtained from American Type Culture Collection (ATCC). Cells lines were maintained as monolayers in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100µg/ml streptomycin sulfate. Cells were sub-cultured with trypsine /EDTA solution, counted with haemocytometer and plated onto 96-well plates (5000 cells/well) and left overnight to form a semi-confluent monolayer. Cell monolayers were treated in quadrates with vehicle (DMSO, 0.1% v/v), test samples (thiazolyl-pyrazolines 7a-o) or Staurosporine as positive control for an exposure time of 48 h. At the end of exposure, MTT solution in PBS (5 mg/ml) was then added to all well including no cell blank and left to incubate for 90 min. The formation of formazan crystals were visually confirmed using phase contract microscopy. DMSO (100 µl/well) was added to dissolve the formazan crystals with shaking for 10 min after which the absorbance was read at 590 nm against no cell blanks on a FLuo Star Optima microplate reader (BMG technologies, Germany). Cell proliferation was calculated comparing the OD values of the DMSO control wells and those of the samples represented as % proliferation to the control. Dose-response experiment was performed on samples producing > or =50% loss of cell proliferation using five serial 2-fold dilutions (50, 25, 12.5, 6.25 and 3.125 μ M) of the sample. IC₅₀ values (concentration of sample causing 50% loss of cell proliferation of the vehicle control) were calculated using non-linear regression curve fitting of the dose response plots on GraphPad Prism V.6.0 software.

2. Cell Cycle Analysis

Breast cancer T-47D cells were treated with thiazolyl-pyrazolines **7g** and **7m** for 24 h (at their IC₅₀ concentration), and then cells were washed twice with ice-cold phosphate buffered saline (PBS). Subsequently, the treated cells were collected by centrifugation, fixed in ice-cold 70% (v/v) ethanol, washed with PBS, re-suspended with 100 µg/mL RNase, stained with 40 µg/mL PI, and analyzed by flow cytometry using FACS Calibur (Becton Dickinson, BD, Franklin Lakes, NJ, USA). The cell cycle distributions were calculated using CellQuest software 5.1 (Becton Dickinson).

3. Annexin V-FITC Apoptosis Assay

Phosphatidylserine externalization was assayed using Annexin V-FITC/PI apoptosis detection kit (BD Biosciences, USA) according to the manufacturer's instructions. Breast cancer T-47D cells were cultured to a monolayer then treated with thiazolyl-pyrazolines **7g** and **7m** at their IC₅₀ concentration. Briefly, cells were then harvested *via* trypsinization, and rinsed twice in PBS followed by binding buffer. Moreover, cells were re-suspended in 100 μ L of binding buffer with the addition of 1 μ L of FITC-Annexin V followed by an incubation period of 30 min at 4 °C. Cells were then rinsed in binding buffer and resuspended in 150 μ L of binding buffer with the addition of 1 μ BS). Cells were then analyzed using the flow cytometer BD FACS Canto II and the results were interpreted with FlowJo7.6.4 software (Tree Star, Ashland, OR, USA).

4. EGFR Kinase Inhibitory Activity

Thiazolyl-pyrazolines **7b**, **7g**, **7l** and **7m** were tested in vitro for inhibition of EGFR tyrosine kinase using ADP-Glo[™] Kinase Assay (Promega, Catalogue No. V3831) which is a luminescent kinase assay that measures ADP formed from a kinase reaction. ADP is converted into ATP which is converted into light by Ultra-Glo[™] Luciferase. The luminescent signal positively correlates with ADP amount and kinase activity.

Protocol: first dilute enzyme, substrate, ATP and inhibitors in Tyrosine Kinase Buffer (40 mM Tris,7.5; 20 mM MgCl₂; 0.1 mg/ml BSA (bovine serum albumin); 2 mM MnCl₂; 50µM DTT), then add to the wells of 384 low volume plate: 1 µl of inhibitor or (5% DMSO), 2 µl of enzyme and 2 µl of substrate/ATP mix. Incubate at room temperature for 60 minutes, add 5 µl of ADP-Glo[™] Reagent, incubate at room temperature for 40 minutes, add 10 µl of Kinase Detection reagent, incubate at room temperature for 30 minutes and finally record luminescence (Integration time 0.5-1second).

6. Molecular Docking Study

All the molecular modeling studies were carried out using Molecular Operating Environment (MOE, 2020.0901) software. All minimizations were performed with MOE until an RMSD gradient of 0.05 kcal mol⁻¹Å⁻¹ with MMFF94x force field and the partial charges were automatically calculated. The X-ray crystallographic structure of Epidermal Growth Factor Receptor (EGFR) co-crystallized with the 4anilinoquinazoline inhibitor Erlotinib (PDB ID: 1M17) was downloaded from the protein data bank. Water molecules and ligands that are not involved in binding were removed. Then, the protein was prepared for docking study using Protonate 3D protocol in MOE with default options. The co-crystalized ligand was used to define the binding site for docking. Triangle Matcher placement method and London dG scoring function were used for docking. Docking setup was first validated by self-docking of the co-crystallized ligand (Erlotinib) in the vicinity of the binding site of the enzyme with energy score (S) = -10.86 kcal/mol and RMSD of 1.46 Å. The ability of the docking protocol to reproduce all the key interactions accomplished by the co-crystallized ligand (Erlotinib) with the key amino acids in the binding site indicated the suitability of the adopted docking protocol for the intended docking study. These interactions include H-bonding with Met769, through water mediated H-bonding with Thr766 and cation- π interaction with Lys721 (Figure S1 and S2). The validated setup was then used for predicting the ligand-target interactions of the compounds of interest.






Figure S1. 2D interaction diagram showing Erlotinib docking pose interactions with the key amino acids in the EGFR binding site.



(A)



(**B)**

Figure S2. A) 2D representation and **B)** 3D representation of the superimposition of the co-crystallized (red) and the docking pose (blue) of Erlotinib in the EGFR binding site with RMSD of 1.46Å. (Ligand Hydrogen atoms were removed for clarity)

6. Cells distribution of Cell cycle




Figure S3. Effect of thiazolyl pyrazolines 7g and 7m on the phases of cell cycle of T-47D cells

7. Characterisation of the key intermediate (5c) and the target compounds (7a-o)

2-(5-(4-Fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one 5c

White crystals (yield 89%), m.p. 191-193 °C; ¹H NMR δ *ppm*: 3.40 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 3.6 Hz, 18.0 Hz), 3.90 (s, 2H, CH₂ of thiazolidenone moiety), 4.11 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 4.8 Hz, 18.0 Hz), 5.87 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 3.6 Hz, 10.8 Hz), 7.14-7.18 (m, 3H, Aromatic protons), 7.28-7.30 (m, 2H, Aromatic protons), 7.58 (s, 1H, Aromatic protons), 7.80-7.84 (m, 1H, Aromatic protons); ¹³C NMR δ *ppm*: 44.47, 60.53, 63.58, 116.32, 128.33, 128.97, 132.19, 132.91, 133.07, 136.85, 156.56, 175.36, 177.64, 187.39; Anal. Calcd. for C₁₆H₁₂FN₃OS₂: C, 55.64; H, 3.50; N, 12.17; found C, 55.81; H, 3.48; N, 12.22;

5-Benzylidene-2-(5-(4-fluorophenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one (7a).

White crystals (yield 85%), m.p. 247-249 °C; IR (KBr, $v \text{ cm}^{-1}$) 1707 (C=O); ¹H NMR δ ppm: 2.39 (s, 3H, CH₃), 3.46 (dd, 1H, H_A of pyrazoline methylene C-4 protons , *J*= 4.4 Hz, 18.4 Hz), 4.12 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.4 Hz), 5.90 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.4

Hz, 11.2 Hz), 7.20-7.24 (m, 2H, Aromatic protons), 7.33-7.37 (m, 4H, Aromatic protons), 7.45 (t, 1H, Aromatic protons, J= 7.2 Hz), 7.53-7.57 (m, 2H, Aromatic protons), 7.65-7.67 (m, 3H, Aromatic protons), 7.79 (d, 2H, Aromatic protons, J= 8.0 Hz); ¹³C NMR δ *ppm*: 21.63 (CH₃), 43.98 (CH₂), 63.51(CH), 116.14, 116.35, 127.21, 128.00, 128.43, 128.53, 128.61, 129.76, 130.08, 130.14, 130.41, 131.42, 134.28, 136.70, 136.73, 142.57, 160.94, 162.01, 163.37 (Aromatic carbons), 170.73 (C=O); Anal. Calcd. for C₂₆H₂₀FN₃OS: C, 70.73; H, 4.57; N, 9.52; found C, 70.91; H, 4.53; N, 9.56.

2-(5-(4-Fluorophenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(4-hydroxybenzylidene)thiazol-4(5H)one (7b).

White crystals (yield 78%), m.p. > 300 °C; IR (KBr, $v \text{ cm}^{-1}$) 3215 (OH) and 1701 (C=O); ¹H NMR δ *ppm*: 2.37 (s, 3H, CH₃), 3.43 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 18.4 Hz), 4.10 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.4 Hz), 5.87 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.0 Hz, 11.2 Hz), 6.92-6.96 (m, 2H, Aromatic protons), 7.18-7.24 (m, 2H, Aromatic protons), 7.30-7.36 (m, 4H, Aromatic protons), 7.50 (d, 2H, Aromatic protons, *J*= 8.0 Hz), 7.56 (s, 1H, Aromatic protons), 7.78 (d, 2H, Aromatic protons, *J*= 8.0 Hz), 7.56 (s, 1H, Aromatic protons), 7.78 (d, 2H, Aromatic protons, *J*= 8.0 Hz), 10.10 (s, 1H, OH); ¹³C NMR δ *ppm*: 21.63 (CH₃), 43.94 (CH₂), 63.39 (CH), 116.12, 116.33, 116.74, 124.28, 125.16, 127.33, 127.94, 128.49, 128.57, 130.06, 131.95, 132.37, 136.86, 136.89, 142.41, 159.90, 160.91, 161.45, 163.34 (Aromatic carbons), 170.66 (C=O); Anal. Calcd. for C₂₆H₂₀FN₃O₂S: C, 68.26; H, 4.41; N, 9.18; found C, 68.07; H, 4.44; N, 9.14.

2-(5-(4-Fluorophenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(4-methoxybenzylidene)thiazol-4(5H)one (7c).

White crystals (yield 82%), m.p. 189-200 °C; IR (KBr, $v \text{ cm}^{-1}$) 1705 (C=O); ¹H NMR δ *ppm*: 2.38 (s, 3H, CH₃), 3.43 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.4 Hz, 18.4 Hz), 3.82 (s, 3H, OCH₃), 4.09 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.4 Hz), 5.86 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.0 Hz, 11.2 Hz), 7.08 (d, 2H, Aromatic protons, *J*= 8.8 Hz), 7.19-7.24 (m, 2H, Aromatic protons), 7.31-7.35 (m, 4H, Aromatic protons), 7.58-7.62 (m, 3H, Aromatic protons), 7.77 (d, 2H, Aromatic protons, *J*= 8.8 Hz); ¹³C NMR δ *ppm*: 21.60 (CH₃), 43.93 (CH₂), 55.84 (OCH₃), 63.41 (CH), 115.25, 115.30, 116.11, 116.32, 125.48, 126.70, 127.23, 127.89, 127.94, 128.47, 128.55, 130.04, 131.45, 132.06, 136.76, 136.79,

142.46, 160.92, 161.05, 161.52, 161.63, 163.35 (Aromatic carbons), 170.66 (C=O); Anal. Calcd. for C₂₇H₂₂FN₃O₂S: C, 68.77; H, 4.70; N, 8.91; found C, 68.67; H, 4.75; N, 8.95.

5-(4-(Dimethylamino)benzylidene)-2-(5-(4-fluorophenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1yl)thiazol-4(5H)-one (7d).

White crystals (yield 84%), m.p. 285-287 °C; IR (KBr, $v \text{ cm}^{-1}$) 1717 (C=O); ¹H NMR δ ppm: 2.39 (s, 3H, CH₃), 3.01 (s, 6H, N(CH₃)₂), 3.42 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.4 Hz, 18.8 Hz), 4.09 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.4 Hz), 5.86 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.4 Hz, 11.2 Hz), 6.82 (d, 2H, Aromatic protons, *J*= 8.0 Hz), 7.19-7.24 (m, 2H, Aromatic protons), 7.31-7.37 (m, 4H, Aromatic protons), 7.47 (d, 2H, Aromatic protons, *J*= 8.4 Hz), 7.53 (s, 1H, Aromatic protons), 7.78 (d, 2H, Aromatic protons, *J*= 8.0 Hz); Anal. Calcd. for C₂₈H₂₅FN₄OS: C, 69.40; H, 5.20; N, 11.56; found C, 69.31; H, 5.16; N, 11.53.

5-(4-Chlorobenzylidene)-2-(5-(4-fluorophenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)one (7e).

White crystals (yield 80%), m.p. 256-258 °C; IR (KBr, $v \text{ cm}^{-1}$) 1709 (C=O); ¹H NMR δ ppm: 2.40 (s, 3H, CH₃), 3.48 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.4 Hz, 18.4 Hz), 4.13 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.6 Hz, 18.4 Hz), 5.90 (dd, 1H, H_x of pyrazoline C-5 proton, *J*= 4.4 Hz, 11.2 Hz), 7.20-7.25 (m, 2H, Aromatic protons), 7.31-7.38 (m, 4H, Aromatic protons), 7.59-7.65 (m, 3H, Aromatic protons), 7.67-7.72 (m, 2H, Aromatic protons), 7.79 (d, 2H, Aromatic protons, *J*= 8.8 Hz); MS *m/z* [%]: 475.93 [M⁺, 60.89], 271.20 [100]; Anal. Calcd. for C₂₆H₁₉ClFN₃OS: C, 65.61; H, 4.02; N, 8.83; found C, 65.83; H, 4.07; N, 8.75.

5-Benzylidene-2-(5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)one (7f).

White crystals (yield 88%), m.p. 236-238 °C; IR (KBr, $v \text{ cm}^{-1}$) 1705 (C=O); ¹H NMR δ ppm: 3.42 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 18.0 Hz), 3.82 (2s, 3H, OCH₃), 4.07 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.0 Hz), 5.85 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.4 Hz, 11.2 Hz), 7.06-7.10 (m, 3H, Aromatic protons), 7.18-7.23 (m, 3H, Aromatic protons), 7.31-7.34 (m, 3H,

Aromatic protons), 7.58-7.60 (m, 3H, Aromatic protons), 7.81 (d, 2H, Aromatic protons, *J*= 8.8 Hz); Anal. Calcd. for C₂₆H₂₀FN₃O₂S: C, 68.26; H, 4.41; N, 9.18; found C, 68.15; H, 4.38; N, 9.15.

2-(5-(4-Fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(4hydroxybenzylidene)thiazol-4(5H)-one (7g) 7f.

White crystals (yield 90%), m.p. > 300 °C; IR (KBr, $v \text{ cm}^{-1}$) 3210 (OH) and 1702 (C=O); ¹H NMR δ ppm: 3.41 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 17.6 Hz), 3.83 (s, 3H, OCH₃), 4.06 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.6 Hz, 18.8 Hz), 5.85 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.0 Hz, 11.2 Hz), 6.93 (d, 2H, Aromatic protons, *J*= 8.8 Hz), 7.05 (d, 2H, Aromatic protons, *J*= 8.8 Hz), 7.18-7.22 (m, 2H, Aromatic protons), 7.31-7.34 (m, 2H, Aromatic protons), 7.50 (d, 2H, Aromatic protons, *J*= 8.4 Hz), 7.56 (s, 1H, Aromatic protons), 7.81 (d, 2H, Aromatic protons, *J*= 8.8 Hz), 10.21 (s, 1H, OH); Anal. Calcd. for C₂₆H₂₀FN₃O₃S: C, 65.95; H, 4.26; N, 8.87; found C, 66.13; H, 4.21; N, 8.83.

2-(5-(4-Fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(4-

methoxybenzylidene)thiazol-4(5H)-one (7h).

White crystals (yield 83%), m.p. 221-223 °C; IR (KBr, $v \text{ cm}^{-1}$) 1711 (C=O); ¹H NMR δ *ppm*: 3.42 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 18.0 Hz), 3.82, 3.83 (2s, 6H, 2 (OCH₃)), 4.07 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.0 Hz), 5.85 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.4 Hz, 11.2 Hz), 7.06-7.10 (m, 4H, Aromatic protons), 7.18-7.23 (m, 2H, Aromatic protons), 7.31-7.34 (m, 2H, Aromatic protons), 7.58-7.60 (m, 3H, Aromatic protons), 7.81 (d, 2H, Aromatic protons, *J*= 8.8 Hz); Anal. Calcd. for C₂₇H₂₂FN₃O₃S: C, 66.52; H, 4.55; N, 8.62; found C, 66.74; H, 4.52; N, 8.66.

5-(4-(Dimethylamino)benzylidene)-2-(5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one (7i).

White crystals (yield 90%), m.p. 283-285 °C; IR (KBr, $v \text{ cm}^{-1}$) 1710 (C=O); ¹H NMR δ *ppm*: 2.99 (s, 6H, N(CH₃)₂), 3.44 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.4 Hz, 18.0 Hz), 3.83 (s, 3H, OCH₃), 4.05 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 10.8 Hz, 18.0 Hz), 5.83 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.4 Hz, 11.2 Hz), 6.79 (d, 2H, Aromatic protons, *J*= 8.8 Hz), 7.18-7.23 (m, 2H, Aromatic protons), 7.30-7.34 (m, 2H, Aromatic protons), 7.45 (d, 2H, Aromatic

protons, J= 8.8 Hz), 7.52 (s, 1H, Aromatic protons), 7.81 (d, 2H, Aromatic protons, J= 8.8 Hz); ¹³C NMR δ ppm: 43.94 (CH₂), 56.52(N(CH₃)₂), 59.73 (OCH₃), 67.46 (CH), 112.58, 114.96, 116.33, 121.14, 121.64, 122.57, 124.47, 125.62, 127.67, 128.43, 129.78, 132.07, 134.13, 135.43, 135.79, 137.30, 140.27, 151.65, 160.82 (Aromatic carbons), 170.15 (C=O); Anal. Calcd. for C₂₈H₂₅FN₄O₂S: C, 67.18; H, 5.03; N, 11.19; found C, 67.08; H, 5.09; N, 11.12.

5-(4-Chlorobenzylidene)-2-(5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1yl)thiazol-4(5H)-one (7j).

White crystals (yield 80%), m.p. 240-243 °C; IR (KBr, $v \text{ cm}^{-1}$) 1712 (C=O); ¹H NMR δ *ppm*: 3.46 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 18.0 Hz), 3.84 (s, 3H, OCH₃), 4.10 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.4 Hz), 5.88 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.0 Hz, 11.2 Hz), 7.08 (d, 2H, Aromatic protons, *J*= 8.8 Hz), 7.19-7.23 (m, 2H, Aromatic protons), 7.32-7.35 (m, 2H, Aromatic protons), 7.58-7.62 (m, 3H, Aromatic protons), 7.65 (d, 2H, *J*= 8.8 Hz), 7.83 (d, 2H, *J*= 8.8 Hz); ¹³C NMR δ *ppm*: 44.00 (CH₂), 55.99 (OCH₃), 63.52 (CH), 114.95, 116.13, 116.35, 122.33, 128.52, 128.60, 129.27, 129.76, 129.84, 129.91, 131.75, 133.24, 134.83, 136.68, 136.71, 160.94, 161.84, 162.64, 163.37 (Aromatic carbons), 170.13 (C=O); MS *m/z* [%]: 392.97 [M⁺, 21.59], 391.98 [100]; Anal. Calcd. for C₂₆H₁₉CIFN₃O₂S: C, 63.48; H, 3.89; N, 8.54; found C, 63.21; H, 3.82; N, 8.60.

5-Benzylidene-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one (7k).

White crystals (yield 84%), m.p. 266-268 °C; IR (KBr, $v \text{ cm}^{-1}$) 1709 (C=O); ¹H NMR δ *ppm*: 3.41 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.4 Hz, 18.0 Hz), 4.14 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.0 Hz), 5.91 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.4 Hz, 11.2 Hz), 7.20-7.25 (m, 3H, Aromatic protons), 7.34-7.37 (m, 2H, Aromatic protons), 7.42-7.56 (m, 4H, Aromatic protons), 7.61-7.67 (m, 3H, Aromatic protons), 7.90-7.93 (m, 1H, Aromatic protons); ¹³C NMR δ *ppm*: 44.54 (CH₂), 63.68 (CH), 116.18, 116.39, 128.35, 128.51, 128.60, 129.02, 129.79, 130.14, 130.43, 131.56, 132.58, 132.68, 133.54, 134.25, 136.54, 157.47, 160.97 (Aromatic carbons), 170.42 (C=O); Anal. Calcd. for C₂₃H₁₆FN₃OS₂: C, 63.72; H, 3.72; N, 9.69; found C, 63.64; H, 3.76; N, 9.65.

2-(5-(4-Fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(4-hydroxybenzylidene)thiazol-4(5H)-one (7l).

White crystals (yield 79%), m.p. 218-220 °C; IR (KBr, $v \text{ cm}^{-1}$) 3224 (OH) and 1714 (C=O); ¹H NMR δ *ppm*: 3.47 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 18.0 Hz), 4.14 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.0 Hz), 5.90 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.0 Hz, 11.2 Hz), 6.93 (d, 2H, Aromatic protons, *J*= 8.0 Hz), 7.19-7.25 (m, 3H, Aromatic protons), 7.31-7.36 (m, 2H, Aromatic protons), 7.48 (d, 2H, Aromatic protons, *J*= 8.0 Hz), 7.57 (s, 1H, Aromatic protons), 7.65 (d, 1H, Aromatic protons, *J*= 8.4 Hz), 7.91 (d, 1H, Aromatic protons, *J*= 8.0 Hz), 10.15 (s, 1H, OH); ¹³C NMR δ *ppm*: 44.50 (CH₂), 63.56 (CH), 116.16, 116.38, 116.82, 124.04, 124.99, 128.46, 128.55, 128.99, 132.16, 132.40, 132.80, 133.36, 136.71, 156.98, 160.12, 160.94 (Aromatic carbons), 170.32 (C=O); Anal. Calcd. for C₂₃H₁₆FN₃O₂S₂: C, 61.46; H, 3.59; N, 9.35; found C, 61.68; H, 3.62; N, 9.32.

2-(5-(4-Fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-5-(4-

methoxybenzylidene)thiazol-4(5H)-one (7m).

White crystals (yield 82%), m.p. 260-262 °C; IR (KBr, $v \text{ cm}^{-1}$) 1700 (C=O); ¹H NMR δ *ppm*: 3.48 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 18.0 Hz), 3.83 (s, 3H, OCH₃), 4.14 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.4 Hz), 5.90 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.0 Hz, 11.2 Hz), 7.10 (d, 2H, Aromatic protons, *J*= 7.2 Hz), 7.20-7.25 (m, 3H, Aromatic protons), 7.32-7.36 (m, 2H, Aromatic protons), 7.59-7.66 (m, 4H, Aromatic protons), 7.91 (d, 1H, Aromatic protons, *J*= 5.2 Hz); Anal. Calcd. for C₂₄H₁₈FN₃O₂S₂: C, 62.19; H, 3.91; N, 9.07; found C, 61.96; H, 3.96; N, 9.03.


5-(4-(Dimethylamino)benzylidene)-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1yl)thiazol-4(5H)-one (7n).


White crystals (yield 80%), m.p. 281-283 °C; IR (KBr, $v \text{ cm}^{-1}$) 1700 (C=O); ¹H NMR δ ppm: 3.01 (s, 6H, N(CH₃)₂), 3.46 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 18.0 Hz), 4.08 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.4 Hz), 5.89 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.0 Hz, 11.2 Hz), 6.83-6.78 (m, 2H, Aromatic protons), 7.18-7.25 (m, 3H, Aromatic protons), 7.32-7.37 (m, 2H, Aromatic protons), 7.54 (s, 1H, Aromatic protons), 7.64-7.66 (m, 1H,


Aromatic protons), 7.87-7.92 (m, 1H, Aromatic protons); Anal. Calcd. for C₂₅H₂₁FN₄OS₂: C, 63.01; H, 4.44; N, 11.76; found C, 62.83; H, 4.40; N, 11.72.


5-(4-Chlorobenzylidene)-2-(5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one (7o).


White crystals (yield 87%), m.p. 264-266 °C; IR (KBr, $v \text{ cm}^{-1}$) 1701 (C=O); ¹H NMR δ ppm: 3.50 (dd, 1H, H_A of pyrazoline methylene C-4 protons, *J*= 4.0 Hz, 18.0 Hz), 4.16 (dd, 1H, H_B of pyrazoline methylene C-4 protons, *J*= 11.2 Hz, 18.4 Hz), 5.92 (dd, 1H, H_X of pyrazoline C-5 proton, *J*= 4.4 Hz, 11.2 Hz), 7.20-7.26 (m, 3H, Aromatic protons), 7.33-7.37 (m, 2H, Aromatic protons), 7.60-7.63 (m, 3H, Aromatic protons), 7.67-7.69 (m, 3H, Aromatic protons), 7.93 (d, 1H, *J*= 5.2 Hz); ¹³C NMR δ ppm: 44.47 (CH₂), 63.73 (CH), 116.19, 116.41, 128.18, 128.52, 128.60, 129.11, 129.86, 130.22, 131.81, 132.69, 133.18, 133.66, 134.93, 135.25, 136.48, 143.17, 155.28, 157.68, 158.44, 164.76 (Aromatic carbons), 170.15 (C=O); MS *m*/*z* [%]: 491.69 [M⁺, 21.23]; Anal. Calcd. for C₂₃H₁₅CIFN₃OS₂: C, 59.03; H, 3.23; N, 8.98; found C, 58.85; H, 3.22; N, 9.06.
























WAGDY-e PROTON_BSU DMSO {C:\data} abeer 16	BRUKER
CI	Current Data Parameters NAME Aug09-2021-abeer EXPNO 140 PROCNO 1
N + S + F + F 7e	F2 - Acquisition Parameters Date_ 20210809 Time 11.07 INSTRUM spect PROBHD 5 mm PABBO BB/ PULPROG zg30 TD 65536 SOLVENT DMSO NS 16 DS 2 SWH 8012.820 Hz FIDRES 0.122266 Hz AQ 4.0894465 sec RG 116.51 DW 62.400 usec DE 6.50 usec TE 299.0 K D1 1.00000000 sec TD0 1
	====== CHANNEL f1 ====== SF01 400.1324710 MHz NUC1 1H P1 10.00 usec PLW1 16.0000000 W
	F2 - Processing parameters SI 65536 SF 400.1300000 MHz WDW EM SSB 0 LB 0.10 Hz GB 0 PC 1.00
- 	0 –1 –2 ppm


15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -<u>3.55</u> <u>19.61</u> <u>10.61</u> <u>10.61</u>
































wagdy-N PROTON_BSU DMSO {C:\data}	abeer 22	Current Data Parameters NAME Aug09-2021-abeer EXPNO 200 PROCNO 1
$ \begin{array}{c} 0 \\ N \\ N \\ S \\ N \\ N \\ N \\ N \\ F \\ S \\ 7n \end{array} $		F2 - Acquisition Parameters Date_ 20210809 Time 11.33 INSTRUM spect PROBHD 5 mm PABBO BB/ PULPROG zg30 TD 65536 SOLVENT DMSO NS 16 DS 2 SWH 8012.820 Hz FIDRES 0.122266 Hz AQ 4.0894465 sec RG 147.93 DW 62.400 usec DE 6.50 usec TE 299.0 K D1 1.00000000 sec TD0 1
		====== CHANNEL f1 ====== SF01 400.1324710 MHz NUC1 1H P1 10.00 usec PLW1 16.00000000 W F2 - Processing parameters SI 65536 SF 400.1300000 MHz WDW EM SSB 0 LB 0.10 Hz GB 0 PC 1.00

15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 ppm

